Serina Therapeutics Inc
SER5.170USD
-0.120-2.27%
終値 08/04, 16:00（ET）15分遅れの株価
51.35M時価総額
損失額直近12ヶ月PER
詳細情報 Serina Therapeutics Inc 企業名
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
企業情報
企業コードSER
会社名Serina Therapeutics Inc
上場日Nov 29, 2018
最高経営責任者「CEO」Mr. Steven Ledger
従業員数12
証券種類Ordinary Share
決算期末Nov 29
本社所在地601 Genome Way,
都市HUNTSVILLE
証券取引所NYSE American Consolidated
国United States of America
郵便番号35806
電話番号12563279630
ウェブサイトhttps://serinatherapeutics.com/
企業コードSER
上場日Nov 29, 2018
最高経営責任者「CEO」Mr. Steven Ledger
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
収益内訳
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
United States
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Wed, May 28
更新時刻: Wed, May 28
株主統計
種類
株主統計
株主統計
比率
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
株主統計
株主統計
比率
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
種類
株主統計
比率
Corporation
41.86%
Individual Investor
21.99%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
1.12%
Hedge Fund
1.10%
Research Firm
0.04%
Other
32.76%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
59
6.70M
67.24%
+259.47K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
2023Q1
65
604.47K
56.02%
-8.31K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Juvenescence Ltd
3.27M
32.78%
--
--
Mar 01, 2025
Puffinus L.P.
904.88K
9.08%
--
--
Mar 01, 2025
McMillan (Helen w)
842.40K
8.45%
+133.79K
+18.88%
Mar 01, 2025
Fisk (Barbara M.)
536.28K
5.38%
+33.81K
+6.73%
Mar 01, 2025
Loya (Miguel)
422.10K
4.23%
--
--
Mar 01, 2025
Ledger (Steven A)
323.66K
3.25%
+95.73K
+42.00%
Mar 28, 2025
Broadwood Capital, Inc.
85.22K
0.85%
--
--
Mar 31, 2025
Waverly Advisors, LLC
67.49K
0.68%
--
--
Mar 31, 2025
Bailey (Gregory Hugh)
67.24K
0.67%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
65.33K
0.66%
+3.26K
+5.25%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
iShares Micro-Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
日付
種類
比率
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
